The aim of this pilot research was to assess the sleep fragmentation influence on amyloid β42 (Aβ42) plasma levels before and after СPAP in patients with obstructive sleep apnea (OSA). Materials and Methods: The study involved 24 patients (mean age of 52.5±2.7 years) with OSA and 20 persons without OSA (mean age of 49.1±8.2 years). All participants underwent overnight polysomnography, The Aβ42 level was determined in blood plasma by an immunoassay method. Patients with OSA were treated with auto-CPAP for 3 months. Results: The research showed the following results in patients with OSA before CPAP, as compared to control: sleep fragmentation 1-2 times, increases in non-rapid eye movement sleep stage by 60% (P<0.05) and arousal index by 55% (P<0.05), and decreases in slow-wave sleep duration by 40% (P<0.05) and rapid-eye-movement sleep by 43% (P<0.05). After CPAPtherapy, a decrease in arousal index by 40% (P<0.05) and apnea/hypopnea index (P<0.05), and increases in oxygen saturation by 17% (P<0.05), the slow-wave sleep duration by 56% (P<0.05) and rapid-eye-movement sleep by 55% (P<0.05) were found. Aβ42 levels were significantly lower in the group with OSA before CPAP-therapy, as compared to the control group and the group with OSA after CPAP-therapy (P<0.05). There were no differences in Aβ42 levels after treatment between control and main group. Conclusion: Moderate and severe OSA is associated with a decrease in Aβ42 plasma level. CPAP-therapy leads to increase this peptide in blood plasma.

Introduction:The high prevalence of obstructive sleep apnea (OSA), which impairs quality of life for numerous patients and leads to various OSA complications, has contributed to the continued interest in this disorder. The role of serotonin (5-HT) in many physiological processes, studies on its connection with the circadian system, and relationship to changes in sleep architecture are insufficient to assess the interaction of this neurotransmitter with nocturnal hypoxia. The aim of this study was to determine changes in sleep patterns and serum serotonin levels before and after positive airway pressure (PAP) therapy in patients with OSA. Methods: The study involved 30 OSA patients (27 men and 3 women) who were treated with PAP for 3 months. Polysomnography using the GRASS TELEFACTOR (USA) and blood collection were conducted before and after PAP courses. Determination of serum serotonin was performed by high-performance liquid chromatography (HPLC). PAP therapy was performed using an automatic Prisma 20A (Germany) continuous positive airway pressure (CPAP) device. Results: The use of PAP for 3 months revealed a significant improvement as measured by sleep data and serotonin levels (before: apnea index [AI] 17.2 eV/h, after: 2.4 eV/h p = 0.001; SpO 2 \ 90% -45.7 min vs. 6.2 min p = 0.001; serotonin 20.3 ng/mL vs. 26.03 ng/mL p = 0.036]. Conclusion: Our results demonstrate an improvement in sleep patterns. There was an increase in serum serotonin levels in OSA patients following PAP therapy, which could be an effect of intermittent hypoxia decline, and could be used as criteria for the effectiveness of PAP and an improvement in sleep quality.

No abstract

No abstract

No abstract